174 related articles for article (PubMed ID: 33602773)
21. C3 Glomerulopathy.
Riedl M; Thorner P; Licht C
Pediatr Nephrol; 2017 Jan; 32(1):43-57. PubMed ID: 27056062
[TBL] [Abstract][Full Text] [Related]
22. C3 glomerulopathy and current dilemmas.
Ito N; Ohashi R; Nagata M
Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657
[TBL] [Abstract][Full Text] [Related]
23. C3 glomerulonephritis with a severe crescentic phenotype.
Ravindran A; Fervenza FC; Smith RJH; Sethi S
Pediatr Nephrol; 2017 Sep; 32(9):1625-1633. PubMed ID: 28593446
[TBL] [Abstract][Full Text] [Related]
24. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
[TBL] [Abstract][Full Text] [Related]
25. New developments in the diagnosis of fibrillary glomerulonephritis.
Nasr SH; Fogo AB
Kidney Int; 2019 Sep; 96(3):581-592. PubMed ID: 31227146
[TBL] [Abstract][Full Text] [Related]
26. DNAJB9 Is a Reliable Immunohistochemical Marker of Fibrillary Glomerulonephritis: Evaluation of Diagnostic Efficacy in a Large Series of Kidney Biopsies.
Gambella A; Pitino C; Barreca A; Nocifora A; Giarin MM; Bertero L; Biancone L; Roccatello D; Papotti M; Cassoni P
Biomedicines; 2022 Aug; 10(9):. PubMed ID: 36140202
[TBL] [Abstract][Full Text] [Related]
27. Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features.
Rosenstock JL; Markowitz GS; Valeri AM; Sacchi G; Appel GB; D'Agati VD
Kidney Int; 2003 Apr; 63(4):1450-61. PubMed ID: 12631361
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological features of C3 glomerulopathy in children: a single-center experience.
Drake KA; Ellington N; Gattineni J; Torrealba JR; Hendricks AR
Pediatr Nephrol; 2020 Jan; 35(1):153-162. PubMed ID: 31667615
[TBL] [Abstract][Full Text] [Related]
29. C3 glomerulopathy in a patient with a history of post-infectious glomerulonephritis.
Nnadi N; Hendricks AR; Torrealba J; Drake KA; Gattineni J
Pediatr Nephrol; 2024 Mar; 39(3):745-748. PubMed ID: 37874356
[TBL] [Abstract][Full Text] [Related]
30. The C3 conundrum.
Lean M; Chacko B
Intern Med J; 2023 Jun; 53(6):1065-1069. PubMed ID: 37278101
[TBL] [Abstract][Full Text] [Related]
31. Fibrillary Glomerulonephritis: An Update.
Rosenstock JL; Markowitz GS
Kidney Int Rep; 2019 Jul; 4(7):917-922. PubMed ID: 31317113
[TBL] [Abstract][Full Text] [Related]
32. Characterization of C3 in C3 glomerulopathy.
Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.
Michels MAHM; Wijnsma KL; Kurvers RAJ; Westra D; Schreuder MF; van Wijk JAE; Bouts AHM; Gracchi V; Engels FAPT; Keijzer-Veen MG; Dorresteijn EM; Volokhina EB; van den Heuvel LPWJ; van de Kar NCAJ
Pediatr Nephrol; 2022 Mar; 37(3):601-612. PubMed ID: 34476601
[TBL] [Abstract][Full Text] [Related]
34. What lies in-between: C3 glomerulopathy with non-hemolytic renal microangiopathy and an ultra-rare C3 variant.
Jandal A; Zhong W; Gopal D; Horner V; Frater-Rubsam L; Djamali A; Bhutani G
Am J Med Sci; 2023 Mar; 365(3):286-293. PubMed ID: 36473547
[TBL] [Abstract][Full Text] [Related]
35. Fibrillary Glomerulonephritis, DNAJB9, and the Unfolded Protein Response.
Andeen NK; Kung VL; Robertson J; Gurley SB; Avasare RS; Sitaraman S
Glomerular Dis; 2022; 2(4):164-175. PubMed ID: 36817290
[TBL] [Abstract][Full Text] [Related]
36. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
Front Immunol; 2021; 12():715704. PubMed ID: 34456924
[TBL] [Abstract][Full Text] [Related]
37. Fibrillary Glomerulopathy with a High Level of Myeloperoxidase-ANCA: A Case Report.
Asakawa T; Asou M; Hara S; Ehara T; Araki M
Case Rep Nephrol; 2020; 2020():6343521. PubMed ID: 32274231
[TBL] [Abstract][Full Text] [Related]
38. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
39. DnaJ Homolog Subfamily B Member 9 Is a Putative Autoantigen in Fibrillary GN.
Andeen NK; Yang HY; Dai DF; MacCoss MJ; Smith KD
J Am Soc Nephrol; 2018 Jan; 29(1):231-239. PubMed ID: 29097624
[TBL] [Abstract][Full Text] [Related]
40. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
